Analyst Price Target is $6.00
▲ +308.30% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Iterum Therapeutics in the last 3 months. The average price target is $6.00, with a high forecast of $6.00 and a low forecast of $6.00. The average price target represents a 308.30% upside from the last price of $1.47.
Current Consensus is
Buy
The current consensus among 1 contributing investment analysts is to buy stock in Iterum Therapeutics. This Buy consensus rating has held steady for over two years.
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Read More